| ○ |
|
門田 守人 |
がん研有明病院・病院長 |
| 消化器外科 |
| Metabolic system alterations in pancreatic cancer patient serum: potential for early detection. Ritchie SA1, Akita H, Takemasa I, Eguchi H, Pastural E, Nagano H, Monden M, et al. BMC Cancer. 2013 Sep 12;13:416. |
| 5-fluorouracil arterial infusion + interferon therapy for highly advanced hepatocellular carcinoma: A multicenter, randomized, phase II study. Monden M, Sakon M, Sakata Y, Ueda Y, Hashimura E; FAIT Research Group. Hepatol Res. 2012 Feb;42(2):150-65. |
| Recurrence-free survival more than 10 years after liver resection for hepatocellular carcinoma. Eguchi S, Kanematsu T, Arii S, Omata M, Kudo M, Sakamoto M, Takayasu K, Makuuchi M, Matsuyama Y, Monden M; Liver Cancer Study Group of Japan. Br J Surg. 2011 Apr;98(4):552-7. |
|
| |
|
澁谷 正史 |
上武大学 学長 |
| 腫瘍学、分子生物学、血管生物学 |
| VEGFR and Type-V RTK Activation and Signaling. Shibuya M. In the Receptor Tyrosine Kinase Book, Edited by Y. Schlessinger et al. Cold Spring Harb Perspect Biol. 2013 Oct 1;5(10). doi:pii: a009092 |
| Inhibition of histone demethylase JMJD1A improves anti-angiogenic therapy and reduces tumor associated macrophages. Osawa T, Tsuchida R, Muramatsu M, Shimamura T, Wang F, Suehiro JI, Kanki Y, Wada Y, Yuasa Y, Aburatani H, Miyano S, Minami T, Kodama T, Shibuya M. Cancer Res. 73:3019-28, 2013. |
| Involvement of Flt-1 (VEGFR-1) in cancer and preeclampsia. Shibuya, M. Proc Jpn Acad Ser B Phys Biol Sci. 87:167-78, 2011. |
|
| |
|
宮園 浩平 |
東京大学大学院医学系研究科分子病理学 教授 |
| 分子病理学、分子腫瘍学 |
| Smad3 and TTF-1/NKX2-1 complex regulates Smad4-independent gene expression. Isogaya K, *Koinuma D, Tsutsumi S, Saito RA, Miyazawa K, Aburatani H, *Miyazono K. Cell Res. 2014, 24 (8): 994-1008. |
| Bone morphogenetic protein-9 inhibits lymphatic vessel formation via activin receptor-like kinase 1 during development and cancer progression. Yoshimatsu Y, Lee YG, Akatsu Y, Taguchi L, Suzuki HI, Cunha SI, Maruyama K, Suzuki Y, Yamazaki T, Katsura A, Oh SP, Zimmers TA, Lee SJ, Pietras K, Koh GY, *Miyazono K, Watabe T. Proc Natl Acad Sci USA. 2013, 110 (47): 18940-18945. |
| MCPIP1 ribonuclease antagonizes dicer and terminates microRNA biogenesis through precursor microRNA degradation. Suzuki HI, Arase M, Matsuyama H, Choi YL, Ueno T, Mano H, Sugimoto K, *Miyazono K. Mol Cell. 2011, 44 (3): 424-436. |
|
| |
|
末松 誠 |
慶應義塾大学医学部教授 |
| 代謝生化学 ガスバイオロジー |
| Reduced methylation of PFKFB3 in cancer cells shunts glucose towards the pentose phosphate pathway. Yamamoto T, Takano N, Ishiwata K, Ohmura M, Nagahata Y, Matsuura T, Kamata A, Sakamoto K, Hishiki T, Suematsu M. Nat Commun 5, 3480, 2014. doi:10.1038/ncomms4480. |
| Hypoxic regulation of the cerebral microcirculation is mediated by a carbon monoxide-sensitive hydrogen sulfide pathway. Morikawa T, Kajimura M, Nakamura T, Hishiki T, Nakanishi T, Yukutake Y, Nagahata Y, Ishikawa M, Hattori K, Takenouchi T, Takahashi T, Ishii I, Matsubara K, Kabe Y, Uchiyama S, Nagata E, Gadalla MM, Snyder SH, Suematsu M. Proc Natl Acad Sci USA 109(4), 1293-1298, 2012. |
| Carbon monoxide : An endogenous modulator of sinusoidal tone in the perfused rat liver. Suematsu, M., Goda, N., Sano. T., Kashiwagi, S., Egawa, T., Shinoda, Y., Ishimura, Y. J Clin Invest 96, 2431-2437, 1995. |
|
| |
|
津金 昌一郎 |
国立がん研究センター・がん予防・検診研究センター長 |
| 疫学・公衆衛生 |
| The JPHC study: design and some findings on the typical Japanese diet. Tsugane S.Jpn J Clin Oncol. 2014 Sep;44(9):777-82. |
| Insulin resistance and cancer: epidemiological evidence. Tsugane S, Inoue M. Cancer Sci. 2010 May;101(5):1073-9. |
| Diet and the risk of gastric cancer: review of epidemiological evidence. Tsugane S, Sasazuki S. Gastric Cancer. 2007;10(2):75-83. |
|
| |
|
田島 和雄 |
三重大学医学部公衆衛生・産業医学分野 客員教授 |
| 疫学、公衆衛生学 |
現代の五大病「がん」Q&A 田島和雄 監修
毎日ムック（毎日新聞社）・完全保存版・30-63頁・2013年
|
| Ethnoepidemiology of HTLV-1 related diseases: Ethnic determinants of HTLV-1 susceptibility and its worldwide dispersal. Sonoda. S., Li, H.C., Tajima, K., Cancer Sci., 2011, 102:295-301. |
| 2q36.3 is associated with prognosis for estorogen receptor-negative breast cancer patients treated with chemotherapy. Li, J., Matsuo, K., Ito, H., Iwata, H., Tajima, K. et al., Nat. Commun., 2014, 5: 4051. |
|
| |
|
山本 雅之 |
東北大学大学院医学系研究科医化学分野教授 |
| 医化学・分子生物学（酸素と医学） |
＜研究論文例＞
Shimizu R, Engel JD and Yamamoto, M. GATA1-related leukaemias. Nature Reviews Cancer 8, 279-287 (2008)
|
＜研究論文例＞
Yamazaki H, Suzuki M, Otsuki A, Shimizu R, Bresnick EH, Engel JD, and Yamamoto M. A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression. Cancer Cell 25, 415-427 (2014)
|
＜学術的発表例＞
Molecular Basis of the KEAP1-NRF2 System Regulating Environmental Stress Response. The 61st Nobel Symposium on Systems Biology and Mechanisms of Transcription, Nobel Forum, Karolinska, Stockholm, October 8, 2014
|
|
| |
|
稲澤 譲治 |
東京医科歯科大学難治疾患研究所・教授 |
| 分子細胞遺伝学 |
| Kozaki K, Imoto I, Mogi S, Omura K, Inazawa J: Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res. 68:2094-2105, 2008 |
| Izumi H, Inoue J, Yokoi S, Hosoda H, Shibata T, Sunamori M, Hirohashi S, Inazawa J, Imoto I: Frequent silencing of DBC1 is by genetic or epigenetic mechanisms in non-small cell lung cancers. Hum Mol Genet.14:997-1007, 2005 |
| Yang ZQ, Imoto I, Fukuda Y, Pimkhaokham A, Shimada Y, Imamura M, Sugano S, Nakamura Y, Inazawa J: Identification of a novel gene, GASC1, within an amplicon at 9p23-24 frequently detected in esophageal cancer cell lines. Cancer Res.60:4735-9, 2000 |
|
| |
|
大津 敦 |
国立がん研究センター先端医療開発センター長 |
| 腫瘍内科 |
| Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Bang YJ, Van Cutsem E, Ohtsu A, et al, Lancet 376: 687-697, 2010 |
| TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Yoshino T, Mizunuma N, Yamazaki K, Nishina T, Komatsu Y, Baba H, Tsuji A, Yamaguchi K, Muro K, Sugimoto N, Tsuji Y, Moriwaki T, Esaki T, Hamada C, Tanase T, Ohtsu A. Lancet Oncol. 13(10):993-1001, 2012 |
| Randomized phase III trial of 5-fluorouracil alone versus 5-fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin C in patients with unresectable advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205). Ohtsu A, Shimada Y, Shirao K, et al. J Clin Oncol, 21: 54-59, 2003 |
|
| |
|
野田 哲生 |
公益財団法人がん研究会
代表理事・常務理事 がん研究所 所長
|
| 分子遺伝学 |
| H. Takeshima, M. Iino, H. Takekura, M. Nishi, J. Kuno, O. Minowa, H. Takano and T. Noda. (1994) Excitation-contraction uncoupling and muscular degeneration in mice lacking functional skeletal muscle ryanodine-receptor gene. Nature, 369: 556-559. |
| H. Shibata, K. Toyama, H. Shioya, M. Ito, M. Hirota, S. Hasegawa, H. Matsumoto, H. Takano, T. Akiyama, K. Toyoshima, R. Kanamaru, Y. Kanegae, I. Saito, Y. Nakamura, K. Shiba and T. Noda. (1997) Rapid colorectal adenoma formation initiated by conditional targeting of the Apc gene. Science, 278: 120-123. |
| R. Yao, Y. Kondoh, Y. Natsume, H. Yamanaka, M. Inoue, H. Toki, R. Takagi, T. Shimizu, T. Yamori, H. Osada and T. Noda. (2014) A small compound targeting TACC3 revealed its different spatiotemporal contributions for spindle assembly in cancer cells. Oncogene, 33: 4242-4252. |
|
| |
|
岩﨑 甫 |
山梨大学融合研究臨床応用推進センター長・副学長 |
| 外科学、臨床薬理、臨床開発学 |
| 「がん化学療法・分子標的治療update 第３章：新薬開発戦略の変化 １：新しい創薬戦略」岩﨑 甫他共著 西條長宏・西尾和人編 中外医学社,(2009) |
| 日本における分子標的薬の薬剤開発の課題と展望、岩﨑 甫 分子標的薬 日本臨床増刊号, p695-702, 2012 |
「アジアでがんを生き延びる 第III部 新規医薬品開発の未来 第９講 アジアでの抗がん剤開発をめぐる状況と製薬企業のあり方」岩﨑 甫 赤座英之・河原ノリエ編 東京大学出版会, (2013)
|
|
| |
|
橋爪 誠 |
九州大学大学院医学研究院先端医療医学講座・教授 |
| 消化器外科 コンピュータ外科 ロボット手術 |
Murata M, Narahara S, Umezaki K, Toita R, Tabata S, Piao J, Abe K, Kang J, Ohuchida K, Cui L, Hashizume M: Liver cell specific targeting by the preS1 domain of hepatitis B virus surface antigen displayed on protein nanocages.
International Journal of Nanomedicine. 7:4353-62, 2012
|
Hashizume M:
MR image-guided surgical robotic system.
International Journal of Computer Assisted Radiology and Surgery 1(1): 203-205, 2006
|
Arata J, Kenmotsu H, Takagi M, Hori T, Miyagi T, Fujimoto H, Kajita Y, Hayashi Y, Chinzei K, Hashizume M:
Surgical bedside master console for neurosurgical robotic system.
Int J CARS 8(1): 75-86, 2013
|
|
| |
|
佐久間 一郎 |
東京大学大学院工学系研究科 |
| 生体医工学、精密工学 |
| Junchen Wang, Etsuko Kobayashi, Ichiro Sakuma, Coarse-to-fine dot array marker detection with accurate edge localization for stereo visual tracking, Biomedical Signal Processing and Control 15,pp49-59, 2015 |
| Kuan Luan, Takashi Ohya, Hongen Liao, Etsuko Kobayashi, Ichiro Sakuma: Vessel bifurcation localization based on intraoperative three-dimensional ultrasound and catheter path for image-guided catheter intervention of oral cancers, Computerized Medical Imaging and Graphics 37, pp:113-122, 2013 |
| 岸宏亮、藤江正克、橋爪誠、佐久間一郎、土肥健純：ロッド駆動型多関節術具とこれを用いたMRI環境対応小型マスタスレーブマニピュレータ、日本ロボット学会誌 Vol.27 No.6：pp652-660、2009 |
|
| |
|
松井 修 |
金沢大学大学院医薬保健学総合研究科特任教授 |
| 放射線医学 |
Matsui O, Kadoya M, Kameyama T, Yoshikawa J, Takashima T, Nakanuma Y, Unoura M,obayashi K, Izumi R, Ida M, et al. Benign and malignant nodules in cirrhotic livers: distinction based on blood supply. Radiology 1991;178:493-7.
|
| Matsui O, Kadoya M, Yoshikawa J, Gabata T, Arai K, Demachi H, Miyayama S, Takashima T, Unoura M, Kogayashi K. Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization. Radiology 1993;188:79-83. |
| Matsui O, Kadoya M, Kameyama T, Yoshikawa J, Arai K, Gabata T, Takashima T, Nakanuma Y, Terada T, Ida M. Adenomatous hyperplastic nodules in the cirrhotic liver: differentiation from hepatocellular carcinoma with MR imaging. Radiology 1989;173:123-6. |
|
| |
|
池原 譲 |
産業技術総合研究所創薬基盤研究部門・上級主任研究員 |
| 病理学、がんと糖鎖 |
| Yamaguchi T, Ikehara S, Nakanishi H, Ikehara Y*. A genetically engineered mouse model developing rapid progressive pancreatic ductal adenocarcinoma. J of Pathology. 2014 ;234:228-38. (* Corresponding author.) |
| Kuno A§, Ikehara Y§, Tanaka Y, Ito K, Matsuda A, Sekiya S, Hige S, Sakamoto M, Kage M, Mizokami M, Narimatsu H. A serum "sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci Rep. 2013; 3:1065. (§ Equally contribution as a first author.) |
池原譲 「糖鎖情報から読み解く、生命活動と病理」.
病理と基礎生命科学との接点 第三回 病理と臨床 2014;32(6): 677-81
|
|
| |
|
横山 晶 |
公益財団法人新潟県保健衛生センター・副理事長 |
| 臨床腫瘍学・呼吸器内科学 |
| 1）Randomized phase III trial comparing weekly docetaxel plus cisplatin versus docetaxel monotherapy every 3 weeks in elderly patients with advanced non-small-cell lung cancer: the intergroup trial JCOG0803/WJOG4307L. Abe T, Takeda K, Ohe Y, Kudoh S, Ichinose Y, Okamoto H, Yamamoto N, Yoshioka H, Minato K, Sawa T, Iwamoto Y, Saka H, Mizusawa J, Shibata T, Nakamura S, Ando M, Yokoyama A, Nakagawa K, Saijo N, Tamura T. J Clin Oncol. 2015 Feb 20;33(6):575-81. |
２）Randomized controlled trial comparing docetaxel-cisplatin combination with weekly docetaxel alone in elderly patients with advanced non-small-cell lung cancer: Japan Clinical Oncology Group (JCOG) 0207. Tsukada H, Yokoyama A, Goto K, Shinkai T, Harada M, Ando M, Shibata T, Ohe Y, Tamura T, Saijo N; Lung Cancer Study Group of the Japan Clinical Oncology Group(JCOG). Jpn J Clin Oncol. 2015
Jan;45(1):88-95.
|
| ３）Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301). Atagi S, Kawahara M, Yokoyama A, Okamoto H, Yamamoto N, Ohe Y, Sawa T, Ishikura S, Shibata T, Fukuda H, Saijo N, Tamura T; Japan Clinical Oncology Group Lung Cancer Study Group. Lancet Oncol. 2012 Jul;13(7):671-8. |
|
| |
|
篠田 雅幸 |
愛知県がんセンター中央病院・名誉院長 |
| 消化器外科学 |
| Masayuki Shinoda, Nobutoshi Ando, Ken Kato, Satoshi Ishikura, Hoichi Kato, Yasuhiro Tsubosa, Keiko Minashi, Hiroshi Okabe, Yusuke Kimura, Tatsuyuki Kawano, Shin-Ichi Kosugi, Yasushi Toh, Kenichi Nakamura, Haruhiko Fukuda and Japan Clinical Oncology Group：Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303).Cancer Science 106; 407-412, 2015 |
| Isao Oze, Keitaro Matsuo, Stoyo Hosono, Hidemi Ito, Miki Watanabe, Shunzo Hatooka, Yasushi Hasegawa, Masayuki Shinoda, Kazuo Tajima and Hideo Tanaka: Coffee and green tea consumption is associated with upper aerodigestive tract cancer in Japan. Int J Cancer 135(2): 391-400, 2014 |
| Naoko Sanuki, Satoshi Ishikura, Masayuki Shinoda, Yoshinori Ito, Kzushige Hayakawa, Nobutoshi Ando: Radiotherapy quality assurance review for a multi-center randomized trial of locally advanced esophageal cancer: the Japan Clinical Oncology Group (JCOG) trial 0303. Int Clin Oncol 17; 105-111,2011 |
|
| |
|
大江 裕一郎 |
国立研究開発法人国立がん研究センター中央病院
呼吸器内科 副院長 呼吸器内科長
|
| |
| Randomized Phase III Study of Cisplatin plus Irinotecan versus Carboplatin plus Paclitaxel, Cisplatin plus Gemcitabine, and Cisplatin plus Vinorelbine for Advanced Non-Small Cell Lung Cancer: Four-Arm Cooperative Study in Japan. Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, Nishiwaki Y, Saijo N, Ariyoshi Y, Fukuoka M. Ann Oncol. 2007; 18: 317-323. |
| Efficacy and safety of two doses of pemetrexed supplemented with folic Acid and vitamin B12 in previously treated patients with non-small cell lung cancer. Ohe Y, Ichinose Y, Nakagawa K, Tamura T, Kubota K, Yamamoto N, Adachi S, Nambu Y, Fujimoto T, Nishiwaki Y, Saijo N, Fukuoka M. Clin Cancer Res. 2008; 14: 4206-4212. |
| AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. Janne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, Haggstrom D, Felip E, Kim JH, Frewer P, Cantarini M, Brown KH, Dickinson PA, Ghiorghiu S, Ranson M. N Engl J Med. 2015; 372: 1689-1699. |
|
| |
|
水谷 修紀 |
東京医科歯科大学名誉教授／特任教授 |
| 小児血液・腫瘍 |
Incidence and survival rates of hematological malignancies in Japanese children and adolescents (2006-2010): based on registry data from the Japanese Society of Pediatric Hematology.
Horibe K, Mizutani S, et al.
Int J Hematol. 2013;98(1):74-88.
|
Process for immune defect and chromosomal translocation during early thymocyte development lacking ATM.
Isoda T, Mizutani S, et al.
Blood. 2012;120(4):789-99.
|
Immunologically silent cancer clone transmission from mother to offspring.
Isoda T, Mizutani S, et al.
Proc Natl Acad Sci U S A. 2009;106(42):17882-5.?
|
|
| |
|
望月 一男 |
伊豆東部総合病院・顧問（杏林大学医学部客員教授） |
| 整形外科（整形腫瘍学） |
＜研究論文＞
1. Kazuo Mochizuki, Yoshiaki Ishii, Hiroshi Yamaguchi, Toshiharu Minabe: Vascularized tissue transplantation in limb salvage procedures for musculoskeletal sarcoma. J Orthop Surg 7(2): 23-32, 1999.
2. Kazuo Mochizuki, Hiroshi Yamaguchi, Tohru Umeda, Japanese Musculo-Skeletal Oncology Group: The management of pelvic chondrosarcoma in Japan. Int Orthop (SICOT) 24(2): 65-70, 2000.
Takashi Tajima, Takeshi Morii, Fumihito Kikuchi, Akihiko Matsumine, Hiroaki Murata, Hiroo Nobuto, Kazuo Mochizuki: Significance of the expression of LRP and PPAR-gamma in lipomatous soft tissue tumors. Open Orthop J 4: 48-55, 2010.
|
＜著作＞
1. 望月一男（分担執筆）：軟部腫瘍.臨床病態学３・北村聖総編集、11運動器疾患.松下隆編集・ヌーヴェルヒロカワ・東京・191-204, 2006.
2. 望月一男（分担執筆）：悪性線維性組織球腫. 吉川秀樹編集・20巻骨軟部腫瘍および関連疾患.越智隆弘総編集・最新整形外科学体系.中山書店・東京・316-319, 2007.
望月一男（編集顧問）：臨床医のための最新整形外科. 平澤泰介、三浪明男、戸山芳昭編集主幹・先端医療シリーズ44.先端医療技術研究所・東京, 2013.
|
＜学術的発表＞
1. Kazuo Mochizuki (Faculty Member): Limb salvage surgery for distal femur osteosarcoma using extendable Kotz prosthesis in children -Video of operation, extension and function. Reconstruction using vascularized tissue transplantation following resection of musculoskeletal sarcomas. Advanced International Course on Lower Extremity Limb Salvage Surgery, Kuala Lumpur, Malaysia, 11-12 June 2007.
2. Kazuo Mochizuki (Invited Lecture): Importance of postoperative managements for malignant musculoskeletal tumors. The 22nd Annual meeting of the Korean Bone and Joint Tumor Society, DaeJeon, Korea, 19-21 April 2012.
望月一男（会長講演）：悪性軟部腫瘍に対するunplanned resectionの問題点. 第45回日本整形外科学会骨・軟部腫瘍学術集会、東京都、2012年7月15日.
|
|
| |
|
眞島 喜幸 |
特定非営利活動法人パンキャンジャパン 理事長 |
| 患者アドボカシー、がん研究支援 |
| 革新的がん医療の分野に関わる業績なし |
|
| |
|
田村 和夫 |
福岡大学医学部腫瘍・血液・感染症内科学 教授 |
| 内科学、臨床腫瘍学、血液学 |
| Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, Fujimoto K, Yamamoto K, Miyamoto T, Uike N, Tanimoto M, Tsukasaki K, Ishizawa K, Suzumiya J, Inagaki H, Tamura K, Akinaga S, Tomonaga M, Ueda R. J Clin Oncol 32(11):1157-63, 2014 |
Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma.
Ishitsuka K, Tamura K. Lancet Oncol 15(11):e517-26, 2014
|
がん治療副作用対策マニュアル 改訂第3版 田村和夫編著 南江堂
2014年7月
|
|
